Current opinion in neurology · 2008
Plasma exchange in immune-mediated neuropathies.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lehmann Helmar C, Hartung Hans-Peter, Meyer Zu Hörste Gerd, Kieseier Bernd C
Аннотация
PURPOSE OF REVIEW: Plasma exchange is frequently used for treatment of immune-mediated neuropathies. Here, we review the current value of plasma exchange in the treatment of different forms of immune-mediated neuropathies and discuss latest developments.
RECENT FINDINGS: Plasma exchange is used in various disease conditions; however, of all immune-mediated disorders of the peripheral nerve, Guillain-Barré syndrome represents the disease entity in which short and long-term efficacy, optimal frequency, side effects and cost effectiveness of plasma exchange are best documented. Although randomized trials evaluated the value of plasma exchange in chronic forms of immune-neuropathies, its long-term efficacy and its optimal frequency still remain unclear.
SUMMARY: Especially in chronic forms of immune-mediated neuropathies, plasma exchange needs to be further evaluated in clinical trials to assess long-term efficacy and its potential as adjuvant treatment option.
RECENT FINDINGS: Plasma exchange is used in various disease conditions; however, of all immune-mediated disorders of the peripheral nerve, Guillain-Barré syndrome represents the disease entity in which short and long-term efficacy, optimal frequency, side effects and cost effectiveness of plasma exchange are best documented. Although randomized trials evaluated the value of plasma exchange in chronic forms of immune-neuropathies, its long-term efficacy and its optimal frequency still remain unclear.
SUMMARY: Especially in chronic forms of immune-mediated neuropathies, plasma exchange needs to be further evaluated in clinical trials to assess long-term efficacy and its potential as adjuvant treatment option.